Verona Pharma
NEWS
Verona Pharma on Wednesday secured the FDA’s approval for Ohtuvayre, which the company contends is the first inhaled chronic obstructive pulmonary disease medicine with a new mechanism of action in over 20 years.
Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree Capital Management and OMERS Life Sciences.
Data analytics firm GlobalData expects potential FDA approvals this year of Sanofi and Regeneron’s Dupixent and Verona’s ensifentrine to transform the treatment of chronic obstructive pulmonary disease.
Verona Pharma has been given a leg up from two financial firms, Oxford Finance and Hercules Capital, securing a debt financing facility to support the potential launch of its COPD drug candidate ensifentrine.
Verona Pharma’s COPD candidate hits the mark in late-stage testing.
The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo with wins in COPD, lung cancer and macular edema respectively.
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease.
Biotech and pharma companies tap new members of executive leadership teams and boards.
JOBS
IN THE PRESS